• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Covid-19 大流行与哮喘:我们从中得到了什么启示?

Covid-19 pandemic and asthma: What did we learn?

机构信息

Imperial College London, National Heart and Lung Institute, London, UK.

出版信息

Respirology. 2023 Jul;28(7):603-614. doi: 10.1111/resp.14515. Epub 2023 May 8.

DOI:10.1111/resp.14515
PMID:37154075
Abstract

This review addresses some of the major lessons we have learnt regarding asthma and the covid-19 pandemic, including susceptibility to SARS-CoV-2 infection and severe covid-19, potentially protective factors, comparison to other respiratory infections, changes in healthcare behaviour from the perspective of patients and clinicians, medications to treat or prevent covid-19, and post-covid syndrome.

摘要

这篇综述探讨了我们在哮喘和 COVID-19 大流行方面所获得的一些重要经验教训,包括对 SARS-CoV-2 感染和重症 COVID-19 的易感性、可能的保护因素、与其他呼吸道感染的比较、从患者和临床医生角度看医疗行为的改变、用于治疗或预防 COVID-19 的药物以及新冠后综合征。

相似文献

1
Covid-19 pandemic and asthma: What did we learn?Covid-19 大流行与哮喘:我们从中得到了什么启示?
Respirology. 2023 Jul;28(7):603-614. doi: 10.1111/resp.14515. Epub 2023 May 8.
2
Asthma, severe acute respiratory syndrome coronavirus-2 and coronavirus disease 2019.哮喘、严重急性呼吸综合征冠状病毒 2 型和 2019 年冠状病毒病。
Curr Opin Allergy Clin Immunol. 2021 Apr 1;21(2):182-187. doi: 10.1097/ACI.0000000000000720.
3
Severe asthma and COVID-19: lessons from the first wave.严重哮喘与 COVID-19:来自第一波疫情的教训。
J Asthma. 2022 Feb;59(2):239-242. doi: 10.1080/02770903.2020.1861622. Epub 2020 Dec 16.
4
Asthma and COVID-19: an update.哮喘与 COVID-19:最新进展。
Eur Respir Rev. 2021 Dec 15;30(162). doi: 10.1183/16000617.0152-2021. Print 2021 Dec 31.
5
Is asthma a risk factor for coronavirus disease-2019 worse outcomes? The answer is no, but ….哮喘是否是导致 2019 冠状病毒病不良结局的危险因素?答案是否定的,但……
Curr Opin Allergy Clin Immunol. 2021 Jun 1;21(3):223-228. doi: 10.1097/ACI.0000000000000734.
6
[COVID-19 and asthma].[新型冠状病毒肺炎与哮喘]
Rev Med Liege. 2020;75(S1):130-132.
7
Infection with SARS-CoV-2 among children with asthma: evidence from Global Asthma Network.儿童哮喘患者感染 SARS-CoV-2:来自全球哮喘网络的证据。
Pediatr Allergy Immunol. 2022 Jan;33(1):e13709. doi: 10.1111/pai.13709. Epub 2021 Dec 11.
8
Viral infections causing asthma exacerbations in the age of biologics and the COVID-19 pandemic.病毒感染在生物制剂和 COVID-19 大流行时代导致哮喘恶化。
Curr Opin Pulm Med. 2024 May 1;30(3):287-293. doi: 10.1097/MCP.0000000000001061. Epub 2024 Feb 26.
9
Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.新型冠状病毒病 2019 与哮喘、变应性鼻炎:分子机制与宿主-环境相互作用。
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):1-7. doi: 10.1097/ACI.0000000000000699.
10
Inhaled corticosteroids for the treatment of COVID-19.吸入性皮质类固醇治疗 COVID-19。
Eur Respir Rev. 2022 Nov 29;31(166). doi: 10.1183/16000617.0099-2022. Print 2022 Dec 31.

引用本文的文献

1
Efficacy and safety of Lactobacillus plantarum GCWB1001 for respiratory health in a double blind randomized placebo controlled trial.植物乳杆菌GCWB1001对呼吸道健康的疗效和安全性:一项双盲随机安慰剂对照试验
Sci Rep. 2025 Jul 2;15(1):22700. doi: 10.1038/s41598-025-04612-1.
2
Outpatient utilization trend of bronchodilator and anti-inflammatory agents in the pandemic and beyond.大流行期间及之后支气管扩张剂和抗炎药的门诊使用趋势。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 8. doi: 10.1007/s00210-025-04099-7.
3
Monitoring Macrophage Polarization in Infectious Disease, Lesson From SARS-CoV-2 Infection.
监测传染病中的巨噬细胞极化:来自新冠病毒感染的经验教训
Rev Med Virol. 2025 May;35(3):e70034. doi: 10.1002/ird3.70006.
4
Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.嗜酸性粒细胞与新冠病毒病:对免疫复杂性和疫苗安全性的见解
Clin Transl Allergy. 2025 Mar;15(3):e70050. doi: 10.1002/clt2.70050.
5
Evaluation of the case fatality rate in 2 031 309 hospitalised Brazilian patients due to COVID-19: An observational study of the first 3 years of the pandemic in Brazil.对2031309名因新冠肺炎住院的巴西患者的病死率评估:巴西大流行前三年的一项观察性研究。
BMJ Public Health. 2025 Mar 15;3(1):e000724. doi: 10.1136/bmjph-2023-000724. eCollection 2025 Jan.
6
Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics.在现实环境中治疗的重度嗜酸性粒细胞性哮喘患者中使用贝那利珠单抗的疗效:中东欧和波罗的海5国的BREEZE研究结果
J Asthma Allergy. 2025 Feb 17;18:195-210. doi: 10.2147/JAA.S503048. eCollection 2025.
7
Key Characteristics of Asthma Patients with COVID-19 Vary Substantially by Age.感染新冠病毒的哮喘患者的关键特征因年龄而异。
J Asthma Allergy. 2024 Jun 22;17:589-600. doi: 10.2147/JAA.S456145. eCollection 2024.
8
Association Between ACE2 and Lung Diseases.血管紧张素转换酶2(ACE2)与肺部疾病之间的关联。
Infect Drug Resist. 2024 May 7;17:1771-1780. doi: 10.2147/IDR.S445180. eCollection 2024.